First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments.
Saved in:
| Title: | First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments. |
|---|---|
| Authors: | Nie, Naifu1 (AUTHOR), Li, Jianghua1 (AUTHOR), Zhang, Jian1 (AUTHOR), Dai, Jie1 (AUTHOR), Liu, Zhulin1 (AUTHOR), Ding, Zhenyu2 (AUTHOR), Wang, Yubo1 (AUTHOR), Zhu, Mengxiao1 (AUTHOR), Hu, Chen1 (AUTHOR), Han, Rui1 (AUTHOR), Tang, Huan1 (AUTHOR), Li, Li1 (AUTHOR) dpyyhxlili@tmmu.edu.cn, He, Yong1 (AUTHOR) |
| Source: | Clinical Medicine Insights: Oncology. 11/11/2022, p1-10. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
